Antioxidant Treatment Rescues An Accelerated Aging Phenotype In Dyskerin Mutated Bone Marrow Stem Cells
Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized riboso...
Saved in:
Published in | Blood Vol. 116; no. 21; p. 2614 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
19.11.2010
|
Online Access | Get full text |
ISSN | 0006-4971 1528-0020 |
DOI | 10.1182/blood.V116.21.2614.2614 |
Cover
Abstract | Abstract 2614
X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized ribosomal RNAs and spliceosomal snRNAs. Dyskerin also associates with telomerase and is involved in telomere maintenance. In addition to the well known effect of telomere homeostasis on cancer, it is evident that telomere maintenance may also be important in replicative aging because of telomere shortening due to the limited expression of telomerase activity in dividing somatic cells. Accumulating evidence suggests that dysfunctional telomeres resulting in premature cellular senescence is the primary cause of bone marrow failure in dyskeratosis congenita. It is important to determine the mechanism whereby Dkc1 mutations lead to premature cellular senescence in bone marrow. We have produced a line of mice containing a mutation, Dkc1Δ15, which is a copy of a pathogenic human mutation. Male Dkc1Δ15 mice showed a decrease in the proportion of B and T lymphocytes in peripheral blood and reduced body weight with age but no overt bone marrow failure syndrome phenotypes. Our previous competitive bone marrow transplantation experiments showed that the Dkc1Δ15 mutation caused decay of stem cell function with age. Bone marrow from older Dkc1Δ15 mice was markedly inefficient in repopulation studies compared with bone marrow from age matched wild type mice. We also found that N-acetyl cysteine (NAC) could at least partially rescue the growth disadvantage of dyskerin mutant spleen cells or fibroblasts which was associated with accumulation of DNA damage and reactive oxygen species. To determine if NAC, or other antioxidants might be useful therapeutically it is important to determine their effects on stem cell function, which is defective in DC. To this end we established a cohort of mice that were given NAC in their drinking water (1mg/ml) from 3-weeks of age and maintained on NAC for 1 year. We found that long term NAC treatment did not show significant side effects on the mice. They had slightly increased neutrophils, but no difference in life span and body weight compared with the untreated group. Impressively, old male Dkc1Δ15 mice showed corrected B and T cell proportions in peripheral blood after treatment with NAC. Competitive bone marrow transplantation experiments were carried out in which a 1:1 mixture of BM cells from mutant and WT mice was used to repopulated lethally irradiated recipient mice. These experiments showed that, when taken from NAC treated animals, old Dkc1Δ15 BM cells could compete with age matched WT cells with 40–45% of Dkc1Δ15 cells in primary recipients compared with only 20% for the untreated group. Moreover, after secondary transplantation, cells from the NAC treated group still represent 15–20% of Dkc1Δ15 cells in recipients while those from the untreated group could not be detected. These results strongly suggest that NAC treatment can partially restore the bone marrow repopulating ability of Dkc1Δ15 stem cells. Together with our previous results these data suggest that a pathogenic Dkc1 mutation, through its effect on telomerase, initiates stem cell aging before telomeres are short and that increased oxidative stress might play a role in this process. Moreover the effects of the mutation may be prevented or delayed by antioxidant treatment, although the precise mechanism will be the subject of future investigation.
Bessler:Alexion Pharmaceutical Inc:Consultancy;Novartis: Membership on an entity's Board of Directors or advisory committees; Taligen: Consultancy. |
---|---|
AbstractList | Abstract 2614
X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized ribosomal RNAs and spliceosomal snRNAs. Dyskerin also associates with telomerase and is involved in telomere maintenance. In addition to the well known effect of telomere homeostasis on cancer, it is evident that telomere maintenance may also be important in replicative aging because of telomere shortening due to the limited expression of telomerase activity in dividing somatic cells. Accumulating evidence suggests that dysfunctional telomeres resulting in premature cellular senescence is the primary cause of bone marrow failure in dyskeratosis congenita. It is important to determine the mechanism whereby Dkc1 mutations lead to premature cellular senescence in bone marrow. We have produced a line of mice containing a mutation, Dkc1Δ15, which is a copy of a pathogenic human mutation. Male Dkc1Δ15 mice showed a decrease in the proportion of B and T lymphocytes in peripheral blood and reduced body weight with age but no overt bone marrow failure syndrome phenotypes. Our previous competitive bone marrow transplantation experiments showed that the Dkc1Δ15 mutation caused decay of stem cell function with age. Bone marrow from older Dkc1Δ15 mice was markedly inefficient in repopulation studies compared with bone marrow from age matched wild type mice. We also found that N-acetyl cysteine (NAC) could at least partially rescue the growth disadvantage of dyskerin mutant spleen cells or fibroblasts which was associated with accumulation of DNA damage and reactive oxygen species. To determine if NAC, or other antioxidants might be useful therapeutically it is important to determine their effects on stem cell function, which is defective in DC. To this end we established a cohort of mice that were given NAC in their drinking water (1mg/ml) from 3-weeks of age and maintained on NAC for 1 year. We found that long term NAC treatment did not show significant side effects on the mice. They had slightly increased neutrophils, but no difference in life span and body weight compared with the untreated group. Impressively, old male Dkc1Δ15 mice showed corrected B and T cell proportions in peripheral blood after treatment with NAC. Competitive bone marrow transplantation experiments were carried out in which a 1:1 mixture of BM cells from mutant and WT mice was used to repopulated lethally irradiated recipient mice. These experiments showed that, when taken from NAC treated animals, old Dkc1Δ15 BM cells could compete with age matched WT cells with 40–45% of Dkc1Δ15 cells in primary recipients compared with only 20% for the untreated group. Moreover, after secondary transplantation, cells from the NAC treated group still represent 15–20% of Dkc1Δ15 cells in recipients while those from the untreated group could not be detected. These results strongly suggest that NAC treatment can partially restore the bone marrow repopulating ability of Dkc1Δ15 stem cells. Together with our previous results these data suggest that a pathogenic Dkc1 mutation, through its effect on telomerase, initiates stem cell aging before telomeres are short and that increased oxidative stress might play a role in this process. Moreover the effects of the mutation may be prevented or delayed by antioxidant treatment, although the precise mechanism will be the subject of future investigation. Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized ribosomal RNAs and spliceosomal snRNAs. Dyskerin also associates with telomerase and is involved in telomere maintenance. In addition to the well known effect of telomere homeostasis on cancer, it is evident that telomere maintenance may also be important in replicative aging because of telomere shortening due to the limited expression of telomerase activity in dividing somatic cells. Accumulating evidence suggests that dysfunctional telomeres resulting in premature cellular senescence is the primary cause of bone marrow failure in dyskeratosis congenita. It is important to determine the mechanism whereby Dkc1 mutations lead to premature cellular senescence in bone marrow. We have produced a line of mice containing a mutation, Dkc1Δ15, which is a copy of a pathogenic human mutation. Male Dkc1Δ15 mice showed a decrease in the proportion of B and T lymphocytes in peripheral blood and reduced body weight with age but no overt bone marrow failure syndrome phenotypes. Our previous competitive bone marrow transplantation experiments showed that the Dkc1Δ15 mutation caused decay of stem cell function with age. Bone marrow from older Dkc1Δ15 mice was markedly inefficient in repopulation studies compared with bone marrow from age matched wild type mice. We also found that N-acetyl cysteine (NAC) could at least partially rescue the growth disadvantage of dyskerin mutant spleen cells or fibroblasts which was associated with accumulation of DNA damage and reactive oxygen species. To determine if NAC, or other antioxidants might be useful therapeutically it is important to determine their effects on stem cell function, which is defective in DC. To this end we established a cohort of mice that were given NAC in their drinking water (1mg/ml) from 3-weeks of age and maintained on NAC for 1 year. We found that long term NAC treatment did not show significant side effects on the mice. They had slightly increased neutrophils, but no difference in life span and body weight compared with the untreated group. Impressively, old male Dkc1Δ15 mice showed corrected B and T cell proportions in peripheral blood after treatment with NAC. Competitive bone marrow transplantation experiments were carried out in which a 1:1 mixture of BM cells from mutant and WT mice was used to repopulated lethally irradiated recipient mice. These experiments showed that, when taken from NAC treated animals, old Dkc1Δ15 BM cells could compete with age matched WT cells with 40–45% of Dkc1Δ15 cells in primary recipients compared with only 20% for the untreated group. Moreover, after secondary transplantation, cells from the NAC treated group still represent 15–20% of Dkc1Δ15 cells in recipients while those from the untreated group could not be detected. These results strongly suggest that NAC treatment can partially restore the bone marrow repopulating ability of Dkc1Δ15 stem cells. Together with our previous results these data suggest that a pathogenic Dkc1 mutation, through its effect on telomerase, initiates stem cell aging before telomeres are short and that increased oxidative stress might play a role in this process. Moreover the effects of the mutation may be prevented or delayed by antioxidant treatment, although the precise mechanism will be the subject of future investigation. Bessler:Alexion Pharmaceutical Inc:Consultancy;Novartis: Membership on an entity's Board of Directors or advisory committees; Taligen: Consultancy. |
Author | Gu, Baiwei Bessler, Monica Fan, Jian-meng Mason, Philip J |
Author_xml | – sequence: 1 givenname: Baiwei surname: Gu fullname: Gu, Baiwei organization: Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA – sequence: 2 givenname: Jian-meng surname: Fan fullname: Fan, Jian-meng organization: Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA – sequence: 3 givenname: Monica surname: Bessler fullname: Bessler, Monica organization: Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA – sequence: 4 givenname: Philip J surname: Mason fullname: Mason, Philip J organization: Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA |
BookMark | eNqFkMtOwzAURC1UJNrCN-AfSPArjy5DeVVqBYLC1nLtm2JI7cpOgf49acqezdy7mBmNzggNnHeA0CUlKaUlu1o13pv0jdI8ZTRlORW9nKAhzViZEMLIAA0JIXkiJgU9Q6MYPwihgrNsiNaVa63_sUa5Fi8DqHYD3fcMUe8g4srhSmtoIKgWDK7W1q3x0zs43-63gGcO3-zjJwTr8GLX9p7rbh5eqBD8N35pYYOn0DTxHJ3Wqolw8XfH6PXudjl9SOaP97NpNU80JblIKCsMV0VWTEoGinMhALgpMl5022vIDNRlrla1mpicC1YLRYlhjFAQK15owceoOPbq4GMMUMttsBsV9pISeeAle17ywEsyKg-oeumS1TEJ3bwvC0FGbcFpMDaAbqXx9t-OX6Tfd_M |
ContentType | Journal Article |
Copyright | 2010 American Society of Hematology |
Copyright_xml | – notice: 2010 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V116.21.2614.2614 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 2614 |
ExternalDocumentID | 10_1182_blood_V116_21_2614_2614 S0006497119446818 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 9M8 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFFNX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N4W N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ AALRI AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AIGII AITUG AKBMS AKRWK AKYEP AMRAJ CITATION EFKBS H13 |
ID | FETCH-LOGICAL-c1064-127d3a757982ea3344ee3d7537497fe5def86abfa9d6342f4a10d2201e4b37c43 |
ISSN | 0006-4971 |
IngestDate | Wed Oct 01 03:04:11 EDT 2025 Fri Feb 23 02:43:41 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 21 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1064-127d3a757982ea3344ee3d7537497fe5def86abfa9d6342f4a10d2201e4b37c43 |
OpenAccessLink | https://dx.doi.org/10.1182/blood.V116.21.2614.2614 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V116_21_2614_2614 elsevier_sciencedirect_doi_10_1182_blood_V116_21_2614_2614 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-11-19 |
PublicationDateYYYYMMDD | 2010-11-19 |
PublicationDate_xml | – month: 11 year: 2010 text: 2010-11-19 day: 19 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2010 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 1.9762558 |
Snippet | Abstract 2614
X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved... |
SourceID | crossref elsevier |
SourceType | Index Database Publisher |
StartPage | 2614 |
Title | Antioxidant Treatment Rescues An Accelerated Aging Phenotype In Dyskerin Mutated Bone Marrow Stem Cells |
URI | https://dx.doi.org/10.1182/blood.V116.21.2614.2614 |
Volume | 116 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1528-0020 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014325 issn: 0006-4971 databaseCode: KQ8 dateStart: 19460101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1528-0020 dateEnd: 20241002 omitProxy: true ssIdentifier: ssj0014325 issn: 0006-4971 databaseCode: DIK dateStart: 19460101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1528-0020 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014325 issn: 0006-4971 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1528-0020 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014325 issn: 0006-4971 databaseCode: AKRWK dateStart: 19460101 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKEIwXBB2I8Ut-QLxEKYnjOClvWQdah4oQ6tDeIjtxR0WXTjQVjP-D_5c720kzGBrjxUqj9JL4vpzP9nd3hLxIYyGZGApfzBLu86iET0rFYAxlwBNVCHB5McB58l4cHPHD4_i41_vZYS2tazUoflwaV_I_WoVzoFeMkr2GZluhcAKOQb_Qgoah_ScdZ0hV_D4voXe8acsY_6hXBRh7XO_LigKGFcwGUXqZKUf04bOulmbddVx5--erLxj-503Wtblmb1lhLSLMy4j8r1NvpBeL1YWN34WrLm9IO2u7ZTH_puctEOyK6iHAzofHOWnn--jSWnygHdkwhCbSBX3ZtR23T-UWIpDUEfrO3DXGVWDBOgsV7ewpJsAOWHDB4NroSocsGyDd2E9hQ0rdWNz8_NPOp5g31nD7B59A3oDBXB8uHmwEdDNr_zbitTxEMwNKWW4E5SgoZ2GOMkxzg9xkiRBYGGN__K7dnOIRs4Ux3Ps62iAIevWXJ7rc6ek4MtN75K6bgdDMwuk-6emqT3ayStbL03P6khpOsNls6ZNbe83R9qipDNgntyeOkLFDTjoQpC0EqYMgzSragSA1EKQtBOm4og0EqYMgRQhSC0GKEKQGgg_I0ds309GB72p3-EUIXq4fsqSMZBInw5RpGUWcax2VMDdOoMdmOi71LBVSzeSwFBHYAy7DoGQAK81VlBQ8eki2KrjhI0LBaQ2HmoErqzjnhVClUomKIw5GRgoR75Kg6dz8zKZoya9Q7C553Sghd56m9SBzANhVf358_fs9IXc2X8xTslV_Xetn4MzW6rmB1i_4fpiG |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antioxidant+Treatment+Rescues+An+Accelerated+Aging+Phenotype+In+Dyskerin+Mutated+Bone+Marrow+Stem+Cells&rft.jtitle=Blood&rft.au=Gu%2C+Baiwei&rft.au=Fan%2C+Jian-meng&rft.au=Bessler%2C+Monica&rft.au=Mason%2C+Philip+J&rft.date=2010-11-19&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=116&rft.issue=21&rft.spage=2614&rft.epage=2614&rft_id=info:doi/10.1182%2Fblood.V116.21.2614.2614&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_V116_21_2614_2614 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |